Epigenetic studies in rhabdomyosarcoma
Epigenetic studies in rhabdomyosarcoma
批准号:
8763513
负责人:
Frederic Barr
金额:
$37.97万
依托单位国家:
美国
项目类别:
财政年份:
--
资助国家:
美国
项目状态:
未结题
起止时间:
至
关键词:
AlgorithmsAzacitidineBioinformaticsBiological AssayCategoriesCell LineChromatinComplementary DNAComputer softwareCpG IslandsCpG dinucleotideCustomCytosineDNADNA MethylationDataDevelopmentDideoxy Chain Termination DNA SequencingEpigenetic ProcessFamilyGene ExpressionGenesGenomicsGoalsHumanHuman GenomeHypermethylationIndividualLaboratoriesLeftMalignant NeoplasmsMeasurementMeasuresMethodologyMethodsMethylationNucleic Acid Regulatory SequencesPAX3 genePAX7 genePilot ProjectsProceduresRNA InterferenceResearchReverse Transcriptase Polymerase Chain ReactionRhabdomyosarcomaSamplingScientistSeriesSiteSoftware DesignSpecimenSuggestionTechnologyTumor Cell LineWorkbasebisulfitedesigninhibitor/antagonistinterestpyrosequencingtumor
中文摘要
该项目的直接目标是研究融合阳性和融合阴性横纹肌肉瘤(RMS)肿瘤之间DNA甲基化的差异。在2013财年,一名工作人员科学家开始对该DNA甲基化项目进行分析,直到该个体于2012年11月离开实验室。从2013年3月到现在,实验室的一位研究遗传学家继续进行这些研究。各种生物信息学策略应用于现有的Infinium Human Methylation 27 BeadChip数据,以识别融合阳性和融合阴性RMS肿瘤之间甲基化差异的基因。采用监督分析比较融合阴性和融合阳性肿瘤中各基因的平均甲基化水平,从而确定两组肿瘤中哪些基因的平均甲基化水平有显著差异。在融合阳性RMS中发现了高甲基化和融合阴性RMS中低甲基化的基因,在融合阳性RMS中发现了低甲基化和融合阴性RMS中发现了高甲基化的基因。由于每个甲基化测量适用于单个CpG位点,当在同一基因中发现多个CpG的关系时,信心和兴趣增加。我们的下一个目标是通过确定融合阴性和阳性RMS肿瘤中较大的含cpg调控区域的甲基化状态来验证所选基因的差异甲基化。我们之所以选择焦磷酸测序,是因为它能够定量评估一个选定的含CpG区域内多个CpG位点的甲基化程度。特别是,该技术测量亚硫酸处理的DNA样品中CpG二核苷酸内多个胞嘧啶的C:T比率,从而确定含CpG区域内这些位点的甲基化状态。由于该程序需要用不含CpG二核苷酸的侧翼引物扩增选定的富含CpG的区域(因此不具有依赖于甲基化状态的可变序列),我们使用现有的PyroMark CpG Assays (Qiagen)(当可用时)或使用PyroMark Assay Design Software 2.0软件设计定制引物。基于这些不同的要求,我们选择了四个在融合阳性RMS肿瘤中潜在高甲基化的基因和四个在融合阴性肿瘤中潜在高甲基化的基因。我们最初使用RMS肿瘤细胞系来制定这种方法。我们的细胞系结果表明,在Infinium Human methylation 27 BeadChip上确定的融合阴性和融合阳性RMS肿瘤之间的甲基化差异在RMS细胞系中并没有完全维持。接下来,我们将使用来自RMS肿瘤样本的DNA,特别是,我们将从27 BeadChip上检测的样本的DNA开始。在另一组研究中,我们分析了四个基因的表达,其中至少有一个CpG位点显示融合阳性和融合阴性RMS肿瘤的甲基化存在实质性差异。对于一个基因,其中两个CpG位点中的一个在融合阳性肿瘤中甲基化程度明显高于融合阴性肿瘤,在融合阴性肿瘤中表达明显更高。对于两个基因,其中多个CpG位点在融合阳性肿瘤中表现出比融合阴性肿瘤更高的甲基化,在融合阳性肿瘤中的表达令人惊讶地更高。最后,对于一个基因,其中两个CpG位点中的一个在融合阴性肿瘤中甲基化程度明显高于融合阳性肿瘤,两个融合亚群之间的表达没有显著差异。
英文摘要
The immediate goal of this project is to investigate difference in DNA methylation between fusion-positive and fusion-negative rhabdomyosarcoma (RMS) tumors. During FY 2013, a staff scientist commenced analysis of this DNA methylation project until that individual left the laboratory in November 2012. A research geneticist in the laboratory then continued these studies from March 2013 to the present. Various bioinformatic strategies were applied to the existing Infinium Human Methylation 27 BeadChip data to identify genes that are differentially methylated between fusion-positive and fusion-negative RMS tumors. Supervised analysis was used to compare mean methylation levels for each gene in the fusion-negative and fusion-positive tumors, and then to determine those genes whose mean methylation levels were significantly different between the two groups of tumors. Genes were found for which there was both evidence of hypermethylation in fusion-positive RMS and hypomethylation in fusion-negative RMS, and other genes were found for which there was evidence of hypomethylation in fusion-positive RMS and hypermethylation in fusion-negative RMS. As each methylation measurement applies to a single CpG site, confidence and interest increased when the relationship was found for more than one CpG in the same gene. Our next goal was to validate the differential methylation of selected genes by determining the methylation status of the larger CpG-containing regulatory region in fusion-negative and positive RMS tumors. We selected pyrosequencing because of its ability to quantitatively assess the extent of methylation of multiple CpG sites within a selected CpG-containing region. In particular, this technology measures the C:T ratio at multiple cytosines within CpG dinucleotides in a bisulfite-treated DNA sample and thereby determines the methylation status of these sites within the CpG-containing region. As this procedure requires amplification of the selected CpG-rich regions with flanking primers that do not contain CpG dinucleotides (and thus do not have a variable sequence dependent on methylation status), we used existing PyroMark CpG Assays (Qiagen) when available or used the PyroMark Assay Design Software 2.0 software to design custom primers. Based on these various requirements, we selected four genes that are potentially hypermethylated in fusion-positive RMS tumors and four genes that are potentially hypermethylated in fusion-negative tumors. We initially used RMS tumor cell lines to work out this methodology. Our cell line results indicate that the methylation differences between fusion-negative and fusion-positive RMS tumors, as determined on the Infinium Human Methylation 27 BeadChip, are not fully maintained in RMS cell lines. We will next use DNA from RMS tumor samples, and in particular, we will start with DNA from the samples assayed on the 27 BeadChip. In a separate set of studies, we assayed expression of four genes for which there was at least one CpG site that showed a substantial difference in methylation between fusion-positive and fusion-negative RMS tumors. For one gene in which one of two CpG sites showed substantially higher methylation in fusion-positive than fusion negative tumors, the expression was significantly higher in the fusion-negative tumors. For two genes in which multiple CpG sites demonstrated higher methylation in fusion-positive than fusion-negative tumors, the expression was surprisingly higher in the fusion-positive tumors. Finally, for one gene in which one of two CpG sites showed substantially higher methylation in fusion-negative than fusion-positive tumors, there was no significant difference in expression between the two fusion subsets.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Studies of gene fusions in rhabdomyosarcoma
-
批准号:10486830
-
项目类别:
-
资助金额:$70.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8763479
-
项目类别:
-
资助金额:$33.5万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:8763485
-
项目类别:
-
资助金额:$40.2万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9153887
-
项目类别:
-
资助金额:$47.33万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Clinical Operations for Laboratory of Pathology
-
批准号:9556867
-
项目类别:
-
资助金额:$66.83万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8349507
-
项目类别:
-
资助金额:$17.03万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9556544
-
项目类别:
-
资助金额:$30.47万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:9153908
-
项目类别:
-
资助金额:$43.38万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8553174
-
项目类别:
-
资助金额:$51.06万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:8938110
-
项目类别:
-
资助金额:$50.65万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:8938081
-
项目类别:
-
资助金额:$41.07万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:9343899
-
项目类别:
-
资助金额:$59.23万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:9556893
-
项目类别:
-
资助金额:$152.37万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Anatomic Pathology Residency Program
-
批准号:10703126
-
项目类别:
-
资助金额:$203.96万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10926196
-
项目类别:
-
资助金额:$74.45万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10014672
-
项目类别:
-
资助金额:$30.76万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:9343894
-
项目类别:
-
资助金额:$29.61万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of amplification in rhabdomyosarcoma
-
批准号:10486826
-
项目类别:
-
资助金额:$54.79万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Epigenetic studies in rhabdomyosarcoma
-
批准号:10486842
-
项目类别:
-
资助金额:$39.14万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
Studies of gene fusions in rhabdomyosarcoma
-
批准号:8349513
-
项目类别:
-
资助金额:$17.03万
-
财政年份:--
-
负责人:Frederic Barr
-
依托单位:
国内基金
海外基金
CRISPR/Cas9全基因组文库筛选Venetoclax/Azacitidine耐药关键基因及其机制研究
-
批准号:82100198
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:胡甜园
-
依托单位: